Background {#Sec1}
==========

Pneumatosis intestinalis (PI) is a rare complication of chemotherapy including cytotoxic and molecular-targeted agents \[[@CR1]\], and is characterized by multiple gas accumulations within the bowel wall. PI mainly occurs when gas enters the submucosal and subserosal tissue of the bowel wall with infiltration of giant cells \[[@CR2]\]. The gas is thought to come from the intraluminal gastrointestinal system, bacterial production, or a pulmonary source \[[@CR3]\]. Besides chemotherapy, PI is associated with various medical conditions, such as collagen-vascular diseases, lupus enteritis, infectious colitis, asthma, acquired immune deficiency syndrome, cystic fibrosis, hematopoietic stem cell transplantation, trauma, and steroid therapy \[[@CR2]--[@CR4]\]. Compared with cytotoxic agents, PI due to molecular-targeted agents is even rarer \[[@CR1], [@CR5]--[@CR12]\], and only several cases have been reported in association with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) \[[@CR1], [@CR13]--[@CR17]\]. Here, we describe a patient with leptomeningeal carcinomatosis (LM) caused by EGFR-mutated lung adenocarcinoma who was treated with gefitinib via a feeding tube after erlotinib-induced PI.

Case presentation {#Sec2}
=================

A 71-year-old Japanese woman was admitted to Toranomon hospital because of reduced consciousness. She had a history of a mastectomy for right breast cancer. Eight months before admission, she came to our hospital because of partial paralysis of her right hand. A chest computed tomography (CT) scan showed a mass in the left upper lobe, as well as mediastinal and left hilar lymphadenopathy. Brain magnetic resonance imaging (MRI) showed multiple brain metastases. The patient was diagnosed with EGFR mutation-positive adenocarcinoma using transbronchial lung biopsy. She received 4 cycles of carboplatin and paclitaxel chemotherapy, and gamma knife treatment followed by whole brain radiation for brain metastases. Although chemotherapy resulted in a partial response, her state of consciousness rapidly worsened in the 2 weeks before admission. Her level of consciousness on admission was a Glasgow Come Scale (GCS) score of 8. She could not speak or move her extremities. A lumbar puncture was performed and cytological examination of her cerebrospinal fluid revealed adenocarcinoma cells. EGFR mutation analysis of cerebrospinal fluid was positive for L858R, but negative for exon 20 T790 M. Erlotinib at 150 mg/day was dissolved in 15 mL of water, and was administered via a feeding tube because she could not swallow a tablet. At the same time, 8 mg/day dexamethasone and glycerin administration were started via drip infusion. The patient's state of consciousness gradually improved to a GCS score of 13, and serum levels of CA19--9 decreased from 3031 U/mL to 292 U/mL. As a side effect of erlotinib, diarrhea of the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 grade 2 developed. Three weeks after receiving erlotinib and steroids, the patient started to vomit and suffered from grade 3 diarrhea. At that time, her body temperature, blood pressure, and pulse rate were 36.8 °C, 105/55 mmHg and 92 b.p.m., respectively. There was no abdominal tenderness on her physical examinations. The laboratory test results showed a normal leukocyte count (4700/mL), and a slightly increased C-reactive protein level (2.4 mg/dL). Arterial blood gas analysis showed alkalemia (pH 7.50). An abdominal radiograph showed a dilated colon and the presence of intraluminal air along the wall of the colon (Fig. [1](#Fig1){ref-type="fig"}). A CT scan of the abdomen demonstrated pneumatosis; there was a thickening of the colon with free air, pneumoretroperitoneum, and pneumomediastinum (Fig. [2](#Fig2){ref-type="fig"}). There were no signs of bowel ischemia or portal venous air. Erlotinib and steroids were stopped, and the patient was managed conservatively with a combination of antibiotics and inhalation of oxygen. Two weeks later, the CT findings of PI were improved. Erlotinib was re-administered without steroids, and PI relapsed 4 weeks later with diarrhea. After improving PI by discontinuation of erlotinib and conservative therapies, gefitinib was administered safely without PI and diarrhea for 3 month. At that time, the EGFR-TKIs afatinib and osimertinib were available in the Japanese market. The number of cells in the cerebral fluid decreased from 132/μL to 37/μL with erlotinib and gefitinib, although the cytology was still positive for adenocarcinoma. The patient died of worsening brain metastases 8 months after the diagnosis of LM.Fig. 1An abdominal radiograph showed a dilated colon and the presence of intraluminal air along the wall of the colon with free air (arrow)Fig. 2A CT scan of the abdomen demonstrated a thickening of the colon with free air, pneumoretroperitoneum, and pneumomediastinum

Discussion {#Sec3}
==========

We describe a patient with LM from EGFR-mutated lung adenocarcinoma who was treated with erlotinib followed by gefitinib through a feeding tube for 8 months. As adverse events of erlotinib, PI and grade 3 diarrhea developed, both of which were resolved after treatment with conservative therapies. Subsequently, gefitinib could be administered without either PI or diarrhea.

The precise mechanism by which gefitinib was administered safely instead of erlotinib in this patient is unclear. In comparison of side effects between erlotinib and gefitinib, hepatotoxicity was more common in gefitinib, but rash was more common in erlotinib; the incidence of diarrhea and interstitial lung disease was almost the same \[[@CR18]\]. However, there have been several reports of successful treatments with erlotinib after gefitinib-induced interstitial lung disease \[[@CR19]--[@CR22]\]. One of these reports suggested the hypothesis that minor differences in the chemical structure between two drugs binding to the common quinazoline and anilino rings might influence the results \[[@CR20]\].

PI can be caused by various agents, such as cyclophosphamide, methotrexate, vincristine, doxorubicin, daunorubicin, cytarabine, fluorouracil, paclitaxel, docetaxel, etoposide, irinotecan, 5 fluorouracil (5-FU), and cisplatin \[[@CR12], [@CR14]\]. PI secondary to molecular-targeted agents is very rare \[[@CR1], [@CR5]--[@CR14]\]. Most patients received molecular-targeted therapy alone, and were treated conservatively for PI \[[@CR1]\]. Regarding EGFR-TKIs, PI was reported following gefitinib and erlotinib treatment in several case reports \[[@CR1], [@CR13]--[@CR17]\] (Table [1](#Tab1){ref-type="table"}). These patients presented with gastrointestinal symptoms, such as diarrhea or constipation, and PI was improved by conservative therapies and discontinuation of TKIs.Table 1Previous case reports of pneumatosis intestinalis following gefitinib and erlotinib treatmentYearAuthorAgeSexEGFR-TKIsCT findingsTreatment2012Shinagare, et al. 1)N.D.N.D.ErlotinibN.D.N.D.2012Iwasaku, et al. 13)82FGefitinibIntramural air within the intestinal wallConservative therapy2012Lee, et al. 14)66FGefitinibIntramural air within the intestinal wall, portal venous air, Infarction of liverConservative therapy2014Hughes, et al. 15)N.D. Three patientsN.D.Erlotinib and pertuzumabN.D.N.D.2015Ando, et al. 16)71MGefitinibIntramural air within the intestinal wall, ascitesConservative therapy2016Maeda, et al. 17)80FGefitinibIntramural air within the intestinal wall, pneumoretroperitoneum,Conservative therapy2017Current case71FErlotinibIntramural air within the intestinal wall, pneumoretroperitoneum, pneumomediastinumConservative therapy*EGFR-TKIs* Epidermal growth factor receptor tyrosine kinase inhibitors*N.D* Not described

The precise mechanism of PI secondary to EGFR-TKIs is unknown. EGFR-TKIs have gastrointestinal toxicities, such as diarrhea, nausea, and vomiting. Gastrointestinal toxicities and the subsequent loss of mucosal integrity of the bowel wall may contribute to PI secondary to EGFR-TKIs. In the present case, we were able to treat the patient with gefitinib and erlotinib-induced PI because she did not experience diarrhea after the switch to gefitinib.

The radiological findings of PI were first reported on abdominal radiograph, and the features were submucosal and subserosal cysts formed in ellipses/circles within the bowel wall \[[@CR23]\]. However, nowadays, CT is more useful for the diagnosis of PI \[[@CR3], [@CR24]\]. Typical CT findings are submucosal and subserosal air within the bowel wall and free air \[[@CR25], [@CR26]\]. Like in our patient, PI is sometimes accompanied by pneumomediastinum, which occurs when retroperitoneal and peritoneal air enters along the para-aortic tissues and exits thorough the esophageal hiatus into the mediastinum \[[@CR27], [@CR28]\].

Conclusions {#Sec4}
===========

PI is one of the side effects of EGFR TKIs, and is usually treated with conservative therapies. In this patient, gefitinib was successfully administered after erlotinib-induced PI.
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